Acquire the license to the best health content in the world
Contact Us

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma

Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM

injection with a needle

TUESDAY, Dec. 8, 2020 (HealthDay News) -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study presented at the annual meeting of the American Society of Hematology, held virtually from Dec. 5 to 8.

Meletios A. Dimopoulos, M.D., from the National and Kapodistrian University of Athens in Greece, and colleagues conducted a multicenter study involving 304 patients with RRMM who had received one or more prior line of therapy, including lenalidomide (len) and proteasome inhibitor (PI) treatment. Patients were randomly assigned to the immunomodulatory drug pomalidomide and dexamethasone (Pd) with or without subcutaneous daratumumab (D-Pd).

After 190 progression-free survival (PFS) events, the primary analysis was performed. The researchers found that the study met its primary end point of improved PFS, with a hazard ratio of 0.63 (95 percent confidence interval. 0.47 to 0.85; P = 0.0018) for patients treated with D-Pd. For the D-Pd and Pd arms, the median PFS was 12.4 and 6.9 months, respectively. Complete response rates or better were 24.5 and 3.9 percent for D-Pd and Pd, respectively.

"Collectively, these data show that D-Pd is an effective and convenient treatment for patients with RRMM who received ≥1 prior therapy, including len and a PI," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Press Release

Abstract

More Information

Physician's Briefing